- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04640935
Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)
Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.
The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.
For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.
The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.
As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Boulogne Billancourt, Francia
- Hopital Ambroise Pare Ap-Hp
-
Brest, Francia
- Centre Hospitalier Universitaire Brest
-
Chambéry, Francia
- Centre Hospitalier Metropole Savoie
-
Créteil, Francia
- Centre Hospitalier Intercommunal de Créteil
-
Grenoble, Francia
- Centre Hospitalier Universitaire Grenoble Alpes
-
Le Chesnay, Francia
- Centre Hospitalier de Versailles André Mignot
-
Lille, Francia
- Centre Hospitalier Universitaire de Lille
-
Lyon, Francia
- Hospices Civils de Lyon
-
Lyon, Francia
- Centre Leon Berard Lyon
-
Mantes-la-Jolie, Francia
- Centre Hospitalier François Quesnay
-
Metz-Tessy, Francia, 74374
- Centre Hospitalier Annecy Genevois
-
Paris, Francia
- Institut Curie
-
Saint-Cloud, Francia
- Institut Curie Saint Cloud
-
Saint-Étienne, Francia
- Institut de Cancérologie Lucien Neuwirth
-
Suresnes, Francia
- Hôpital Foch
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- At least 18 years old;
- Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
- Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
- Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
- Alive patients not opposed to the use of their data
Exclusion Criteria:
- Patient under guardianship or curatorship at the date of the study ;
- Patients alive at the time of the study who are opposed to the use of their data
- Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival
Lasso di tempo: Up to 12 months
|
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
|
Up to 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Drugs administration dosage description
Lasso di tempo: Up to 12 months
|
Description of the different monthly drug administration regimens
|
Up to 12 months
|
|
Objective response rate and control rate
Lasso di tempo: Up to 12 months
|
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
|
Up to 12 months
|
|
Overall survival Rate
Lasso di tempo: Up to 12 months
|
Overall survival, assessed on the whole population
|
Up to 12 months
|
|
Objective Response Rate
Lasso di tempo: Up to 12 months
|
Objective Response Rate in the following subgroups:
|
Up to 12 months
|
|
Progression-Free Survival Rate
Lasso di tempo: Up to 12 months
|
Progression-Free Survival in the following subgroups:
|
Up to 12 months
|
|
Disease Control Rate
Lasso di tempo: Up to 12 months
|
Disease Control in the following subgroups:
|
Up to 12 months
|
|
Overall Survival Rate
Lasso di tempo: Up to 12 months
|
Overall Survival in the following subgroups:
|
Up to 12 months
|
|
Frequency of safety events
Lasso di tempo: Up to 12 months
|
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
|
Up to 12 months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Chantal Decroisette, CH Annecy Genevois
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 19-09
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .